CD43 Marker Isolation of Hematopoietic Progenitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and isolating hematopoietic progenitors from human embryonic stem cells (hESCs) are limited by the reliance on CD45 expression, which is not present in early stages of development, making it difficult to distinguish these cells from endothelial cells and limiting the generation of large numbers of lymphohematopoietic cells for research and therapeutic applications.
Innovation Solution
The use of CD43 as a marker to identify and isolate hematopoietic progenitors, allowing for the separation of CD34+ cells into CD43+ and CD43− populations, which includes the identification of CD43+CD45− cells as multipotent lymphohematopoietic progenitors capable of forming all colony-forming cell types and lymphoid cells, and the development of a protocol for generating large numbers of human lymphohematopoietic cells through coculture with OP9 stromal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CD45 expression is used to identify hematopoietic progenitors, then hematopoietic cells can be identified in later stages, but early stage hematopoietic progenitors cannot be distinguished from endothelial cells
Solution Approach 1:
The patent segments the hematopoietic differentiation process into distinct stages based on marker expression. Early progenitors are identified as CD34+CD43+CD45- while later progenitors are CD34+CD43+CD45+. This segmentation allows specific identification strategies for each stage, resolving the contradiction between early identification and accurate characterization.
Solution Approach 2:
The patent utilizes changes in marker expression parameters over time to identify different stages of hematopoietic differentiation. By monitoring the dynamic expression of CD34, CD43, and CD45 markers, the method enables identification of early progenitors that would otherwise be indistinguishable from endothelial cells.
2Manufacturing precision
If CD45 marker is relied upon for isolation, then mature hematopoietic cells can be separated, but early multipotent progenitors are lost
Solution Approach 1:
The patent applies preliminary action by using CD34 and CD43 markers to isolate early multipotent progenitors before they lose their differentiation potential and before CD45 expression becomes prominent. This preliminary isolation captures cells at the optimal stage for maintaining versatility while achieving sufficient purity.
Solution Approach 2:
The patent applies local quality by using different marker combinations for different isolation purposes. CD34+CD43+CD45- marking strategy is used specifically for capturing early multipotent progenitors, while CD45-based markers are used for later stages, optimizing both purity and adaptability for each specific application.
3Quantity of substance
If early hematopoietic progenitors are isolated without CD45 expression, then multipotent progenitors can be captured, but separation from endothelial cells becomes difficult
Solution Approach 1:
The patent merges multiple marker detections (CD34 and CD43 co-expression) to identify early hematopoietic progenitors. This combination approach allows capture of multipotent progenitors in sufficient quantities while providing a reliable distinction from endothelial cells through the specific CD34+CD43+ phenotype pattern.
Data Source
AI summary
This invention relates to hematopoietic precursors derived from human embryonic stem cells. In the culture of differentiated cells from human ES cells, the fully committed hematopoietic precursors are CD34+ and CD43+ but not CD45+. If the cells are cultured until they express CD45, then the cells lose the ability to produce differentiated cells of the lymphoid lineages.